A new vaccine that could help prevent some cases of life-threatening meningococcal disease was approved by the FDA on Wednesday.
Trumenba is approved to protect people between the ages of 10 and 25 from invasive meningococcal disease caused by Neisseria meningitidis serogroup B bacteria.
The bacteria can infect the bloodstream (sepsis) and the lining that surrounds the spinal cord and brain. It is a leading cause of bacterial meningitis, and infection can occur through coughing, kissing or sharing eating utensils.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive